<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03134534</url>
  </required_header>
  <id_info>
    <org_study_id>RuijinH-Robot1</org_study_id>
    <nct_id>NCT03134534</nct_id>
  </id_info>
  <brief_title>Robot-assisted vs VATS Lobectomy for NSCLC</brief_title>
  <official_title>The Study of Robot-assisted Thoracoscopic Surgery Versus Video-assisted Thoracoscopic Surgery Lobectomy for Non-small Cell Lung Cancer on Short-term and Long-term Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Robot-assisted thoracoscopic surgery (RATS) was widely used in thoracic surgery, the surgical
      safety and feasibility of RATS lobectomy for NSCLC has been confirmed. However, the
      oncological long-term outcomes of RATS lobectomy has not been studied by randomized
      controlled trial, the purpose of this study is to determine whether RATS lobectomy would be
      as effective as VATS lobectomy on short-term and long-term outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Video-assisted thoracoscopic surgery (VATS) lobectomy is recommended for non small cell lung
      cancer (NSCLC) with surgical indications in China, its oncological long-term outcomes has
      been widely approved. As a new form of VATS, robot-assisted thoracoscopic surgery (RATS) was
      widely used in thoracic surgery, the 3D vision and flexible robot arm were helpful for
      surgeons to perform precise operations, and RATS was reported to bring extra benefits to
      patients. The surgical safety and feasibility of RATS lobectomy for NSCLC has been confirmed.
      However, the oncological long-term outcomes of RATS lobectomy has not been studied by
      randomized controlled trial. so we designed this randomized controlled trial to determine
      whether RATS lobectomy would be as effective as VATS lobectomy on short-term and long-term
      outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year overall survival (OS)</measure>
    <time_frame>3 year after surgery</time_frame>
    <description>OS at 3 year after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year disease-free survival (DFS)</measure>
    <time_frame>3 year after surgery</time_frame>
    <description>DFS at 3 year after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival (OS)</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>OS at 1 year after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year disease-free survival (DFS)</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>DFS at 1 year after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 rate</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>R0 radical rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dissection of lymph nodes</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>number of harvested lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>margin state</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>positive margin rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative time</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>the time of operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood loss</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>blood loss in the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>conversion rate</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>the rate of conversion to open surgery in the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative accident event</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>the accident event happened in operative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>30-day mortality after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay (LOS)</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>length of stay in hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>mainly include: pneumonia, arrhythmia, incision infection, vocal cord paralysis, trachea cannula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QOL) at 3 month</measure>
    <time_frame>at 3 month after surgery</time_frame>
    <description>QOL, WHOQOLâ€”BREF</description>
  </secondary_outcome>
  <other_outcome>
    <measure>total hospitalization expenditures</measure>
    <time_frame>postoperative in-hospital stay up to 30 days</time_frame>
    <description>cost in hospital</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pulmonary Neoplasm</condition>
  <arm_group>
    <arm_group_label>VATS group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgical procedure: VATS lobectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RATS group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgical procedure: RATS lobectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VATS lobectomy</intervention_name>
    <description>a minimal invasive surgical types for NSCLC: VATS lobectomy</description>
    <arm_group_label>VATS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RATS lobectomy</intervention_name>
    <description>a minimal invasive surgical types for NSCLC: RATS lobectomy</description>
    <arm_group_label>RATS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. surgical indication for lobectomy;

          2. minimal invasive surgery;

          3. ASA (American Society of Anesthesiologists) stage: I-III;

          4. sign the informed consent. -

        Exclusion Criteria:

          1. benign tumor or nodule;

          2. present of other malignancy;

          3. preoperative chemotherapy, radiotherapy, targeted therapy. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>He-Cheng Li, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ding-Pei Han, doctor</last_name>
    <phone>00862164370045</phone>
    <phone_ext>666112</phone_ext>
    <email>dmhan1985@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Run-Sen Jin, doctor</last_name>
    <phone>00862164370045</phone>
    <phone_ext>666112</phone_ext>
    <email>nkvincent@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai JiaoTong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ding-Pei Han, master</last_name>
      <phone>00862164370045</phone>
      <phone_ext>666112</phone_ext>
      <email>dmhan1985@163.com</email>
    </contact>
    <contact_backup>
      <last_name>He-Cheng Li, doctor</last_name>
      <phone>00862164370045</phone>
      <phone_ext>666112</phone_ext>
      <email>lihecheng2000@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ding-Pei Han, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Run-Sen Jin, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ya-Jie Zhang, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Xiang, bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai Chen, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hai-Lei Du, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia-Ming Che, bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun-Biao Hang, bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liang-Gang Zhu, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiao-Qing Yang, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiang Zhou, master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian Ren, bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Hecheng Li M.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>lobectomy</keyword>
  <keyword>robot-assisted thoracoscopic surgery</keyword>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

